REMUS — Remus Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- IN₹11.30bn
- IN₹11.35bn
- IN₹450.27m
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final |
Cash | ||||
Cash and Short Term Investments | 12 | 8.3 | 11.5 | 30.4 |
Net Total Accounts Receivable | ||||
Net Total Receivables | 31.3 | 55.2 | 49.6 | 80.2 |
Total Inventory | ||||
Total Current Assets | 47.6 | 75 | 76.9 | 113 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 5.01 | 3.92 | 3.08 | 25.1 |
Net Intangible Assets | ||||
Long Term Investments | ||||
Long Term Notes Receivable | ||||
Other Long Term Assets | ||||
Total Assets | 53 | 110 | 159 | 347 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 29.3 | 76.9 | 92 | 81.6 |
Long Term Debt | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Deferred Income Tax | ||||
Total Other Liabilities | ||||
Total Liabilities | 32.8 | 80 | 94.8 | 155 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Total Equity | 20.2 | 30.5 | 64.3 | 191 |
Total Liabilities & Shareholders' Equity | 53 | 110 | 159 | 347 |
Total Common Shares Outstanding |